Key hire
Exonate appoints Olav Hellebø as Chief Executive Officer
Uniseed's news page announces that Exonate has named Olav Hellebø its new chief executive.
Company
Exonate
Funding history
Investors
Every investor coverage indicates participated in a round Exonate raised.
On a portfolio page
Investors whose own portfolio pages list Exonate, even though we haven't found any coverage of the round yet.
| Investor | Listed on |
|---|---|
| Stoic Venture Capital | its portfolio page ↗ |
What Exonate bought
Companies Exonate acquired or merged with, per published coverage. Buying a company is not investing in one: nothing here counts in the deals column.
People
| Name | Role | Sources |
|---|---|---|
| Dr Catherine Beech | Chief Executive | cambridgeangels.com |
| Olav Hellebø | Chief Executive Officer | Uniseed (Thu 2 Jul 2026), Uniseed (Thu 2 Jul 2026) |
Coverage
Stories naming Exonate. Where several outlets covered the same round, they are bundled under whichever ran the fullest account.
Key hire
Exonate appoints Olav Hellebø as Chief Executive Officer
A short post on Uniseed's site reports a leadership change at Exonate, with Olav Hellebø taking the chief executive role.
Unnamed stage
£1.5m
Exonate fundraises £1.5 million
Exonate has closed a £1.5 million round, its fourth, to advance an eye-drop therapy for retinal blood-vessel disease toward clinical trials; backers include Uniseed, Angel CoFund, Wren Capital and O2h Ventures.